Wellgistics Health Launches Diabetes Drug Brenzavvy to Pharmacy Network

Wellgistics Health, Inc. has announced the launch of its diabetes drug Brenzavvy® within its network of over 6,500 pharmacies. Targeting the $16 billion SGLT-2 inhibitor market in the United States, this launch aims to serve the 33 million Americans with type II diabetes, focusing on reducing out-of-pocket costs. Brenzavvy is positioned as a cost-effective alternative to current market leaders like Jardiance®, especially for uninsured and underinsured patients.

The company's proprietary EinsteinRx™ platform will enable pharmacies to educate patients on the benefits of Brenzavvy. This initiative is expected to enhance access to this medication and support pharmacists through patient-education revenue opportunities. By integrating advanced technology, Wellgistics aims to improve the care experience and provide a new model for drug reformulation and distribution in rural areas.